Effectiveness and safety of the SREBP1/2 inhibitor, fatostatin, in a preclinical model of metabolic dysfunction-associated steatotic liver disease progression
Mahak Arora, Nikolina Kutinová Canová, Tijana Šopin, Zuzana Pavlíková, Tomáš Kučera, Tomáš Vacı́k, Ondřej Slanař
Topics & Concepts
LipotoxicityEndocrinologyInternal medicineSteatosisSteatohepatitisFatty liverLipid metabolismMedicineLiver diseaseCholesterolBiologyPharmacologyInsulin resistanceDiseaseDiabetes mellitusLiver Disease Diagnosis and TreatmentCholesterol and Lipid MetabolismPeroxisome Proliferator-Activated Receptors